Daclizumab Product Approval Information - Licensing Action

Proper name: Daclizumab
Tradename: Zenapax
Manufacturer: Hoffman-La Roche Inc, Nutley, NJ, License #0136
Indication for Use: Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids
Approval Date: 12/10/97
Type of submission: Biologics license application

Approval Letter (PDF)

Label (PDF)

Reviews (PDF)
    Clinical (43 pages)
    Clinical Pharmacology (22 pages)
    Nonclinical Pharmacology and Toxicology (12 pages)
    Safety (16 pages)
    Chemistry Review (12 pages)

Page Last Updated: 12/18/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English